BR112012012003A2 - anticorpos humanizados contra il-22ra humano. - Google Patents

anticorpos humanizados contra il-22ra humano.

Info

Publication number
BR112012012003A2
BR112012012003A2 BR112012012003A BR112012012003A BR112012012003A2 BR 112012012003 A2 BR112012012003 A2 BR 112012012003A2 BR 112012012003 A BR112012012003 A BR 112012012003A BR 112012012003 A BR112012012003 A BR 112012012003A BR 112012012003 A2 BR112012012003 A2 BR 112012012003A2
Authority
BR
Brazil
Prior art keywords
humanized antibodies
human
dermatife
atopic
psoriasis
Prior art date
Application number
BR112012012003A
Other languages
English (en)
Inventor
Caroline Johnson-Leger
Roland Beckmann
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012012003(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of BR112012012003A2 publication Critical patent/BR112012012003A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

patente de invenção: anticorpos humanizados contra il-22ra humano. a invenção refere-se a anticorpos humanizados contra il-22ra humano e ao seu uso no tratamento de psoríase e outras doenças imune mediadas tal como artrite psoriática e dermatife atópica.
BR112012012003A 2009-11-19 2010-11-12 anticorpos humanizados contra il-22ra humano. BR112012012003A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
BR112012012003A2 true BR112012012003A2 (pt) 2016-11-29

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012003A BR112012012003A2 (pt) 2009-11-19 2010-11-12 anticorpos humanizados contra il-22ra humano.

Country Status (19)

Country Link
US (1) US8545844B2 (pt)
EP (1) EP2512511B1 (pt)
JP (1) JP5818804B2 (pt)
KR (1) KR20120098783A (pt)
CN (1) CN102665759B (pt)
AU (1) AU2010321047B2 (pt)
BR (1) BR112012012003A2 (pt)
CA (1) CA2778864C (pt)
EA (1) EA021356B1 (pt)
EC (1) ECSP12011980A (pt)
ES (1) ES2531996T3 (pt)
IL (1) IL219740A0 (pt)
IN (1) IN2012DN03362A (pt)
MX (1) MX2012005791A (pt)
NZ (1) NZ599438A (pt)
PE (1) PE20121560A1 (pt)
UA (1) UA105405C2 (pt)
WO (1) WO2011061119A1 (pt)
ZA (1) ZA201202793B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005022475D1 (de) * 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
ES2670874T3 (es) 2011-03-16 2018-06-01 Argenx Bvba Anticuerpos contra CD70
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CA2944712A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10654932B2 (en) * 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
US11883464B2 (en) * 2016-03-18 2024-01-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor fusion protein, preparation method and use thereof
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
US10781265B2 (en) * 2017-05-24 2020-09-22 Development Center For Biotechnology Humanized antibodies against Globo H and uses thereof in cancer treatments
WO2019000105A1 (en) 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
DE602005022475D1 (de) * 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
EP1871882A1 (en) * 2005-03-25 2008-01-02 GlycArt Biotechnology AG Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
RU2426742C2 (ru) * 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами

Also Published As

Publication number Publication date
UA105405C2 (ru) 2014-05-12
IN2012DN03362A (pt) 2015-10-23
CA2778864A1 (en) 2011-05-26
KR20120098783A (ko) 2012-09-05
PE20121560A1 (es) 2012-12-05
EA201290360A1 (ru) 2012-11-30
EA021356B1 (ru) 2015-05-29
MX2012005791A (es) 2012-07-03
JP2013511267A (ja) 2013-04-04
NZ599438A (en) 2013-12-20
JP5818804B2 (ja) 2015-11-18
EP2512511A1 (en) 2012-10-24
CN102665759B (zh) 2015-09-30
CA2778864C (en) 2017-06-27
US20120230990A1 (en) 2012-09-13
US8545844B2 (en) 2013-10-01
WO2011061119A1 (en) 2011-05-26
EP2512511B1 (en) 2015-01-07
AU2010321047A1 (en) 2012-05-24
CN102665759A (zh) 2012-09-12
ECSP12011980A (es) 2012-07-31
ZA201202793B (en) 2013-06-26
ES2531996T3 (es) 2015-03-23
AU2010321047B2 (en) 2016-06-09
IL219740A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
BR112012012003A2 (pt) anticorpos humanizados contra il-22ra humano.
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
MX2009011500A (es) Anticuerpos anti-mdl-1.
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
MX2011010707A (es) Anticuerpos dkk-1.
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
IN2012DN01920A (pt)
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
GB201109238D0 (en) Antibodies
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
GB201215873D0 (en) Compositions and methods relating to the treatment of allergy and allergic diseases
BR112013018454A2 (pt) "anticorpo anti-p-selectina e seu uso no tratamento ou inibição de doenças trombóticas e inflamatórias, bem como composição que o compreende"
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
EA201200028A1 (ru) Альфа-1 мультимеры hla-g и их фармацевтическое применение
GB201018154D0 (en) Method of treatment
CY1117566T1 (el) Αγωγη νευροεκφυλιστικων νοσηματων με πορφυρινη

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]